Geode Capital Management LLC recently announced the acquisition of new stake in Aridis Pharmaceuticals Inc. (NASDAQ:ARDS). The institutional investor has increased its shareholding in the Healthcare company by 23.43% to 0.14 million shares with purchase of 25821.0 shares. This fresh investment now brings its stake to 0.65% valued currently at $0.16 million. In addition, Citadel Securities LLC raised its holdings by 34905.0 to 54386.0 shares.
With over 0.93 million Aridis Pharmaceuticals Inc. (ARDS) shares trading Friday and a closing price of $1.18 on the day, the dollar volume was approximately $1.1 million. The shares have shown a positive half year performance of 2.61% and its price on 01/20/23 lost nearly -7.81%. Currently, there are 17.70M common shares owned by the public and among those 17.60M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 2 analysts who have offered their price forecasts for ARDS have a consensus price objective of $10.50. The analysts have set the share’s price value over the next 12 months at a high of $19.00 and a low of $2.00. The average price target is 88.76% above its recent price level and an upside to the estimated low will see the stock gain 41.0% over that period. But an upside of 93.79% will see the stock hit the forecast high price target while median target price for the stock is $10.50.
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Aridis Pharmaceuticals Inc. are Roumell Opportunistic Value Fund, Vanguard Total Stock Market Index, and Vanguard Extended Market Index Fu. Roumell Opportunistic Value Fund owns 0.45 million shares of the company’s stock, all valued at over $0.53 million. Vanguard Extended Market Index Fu bought 331.0 shares to bring its total holdings to over 0.13 million shares at a value of $0.15 million. Vanguard Extended Market Index Fu now owns shares totaling to 0.62% of the shares outstanding.
However, the script later moved the day high at 1.4200, down -7.81%. The company’s stock has a 5-day price change of -6.22% and 18.00% over the past three months. ARDS shares are trading 0.00% year to date (YTD), with the 12-month market performance down to -16.31% lower. It has a 12-month low price of $0.68 and touched a high of $2.94 over the same period. ARDS has an average intraday trading volume of 108.02K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -2.22%, 13.75%, and -6.29% respectively.
Institutional ownership of Aridis Pharmaceuticals Inc. (NASDAQ: ARDS) shares accounts for 10.20% of the company’s 17.70M shares outstanding. Mutual fund holders own 5.36%, while other institutional holders and individual stakeholders account for 6.95% and 4.88% respectively.
It has a market capitalization of $26.60M and a beta (3y monthly) value of 1.21. The earnings-per-share (ttm) stands at -$1.93. Price movements for the stock have been influenced by the stock’s volatility, which stands at 17.05% over the week and 16.53% over the month.
Analysts forecast that Aridis Pharmaceuticals Inc. (ARDS) will achieve an EPS of -$0.17 for the current quarter, $0.13 for the next quarter and -$0.88 for 2023. The lowest estimate earnings-per-share for the quarter is -$0.49 while analysts give the company a high EPS estimate of $0.45. Comparatively, EPS for the current quarter was -$1.94 a year ago. Earnings per share for the fiscal year are expected to decrease by -54.70%, and 68.80% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 2 brokerage firm advisors rate Aridis Pharmaceuticals Inc. (ARDS) as a “Moderate Buy” at a consensus score of 2.30. Specifically, 2 Wall Street analysts polled rate the stock as a buy, while 0 of the 2 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the ARDS, a number of firms have released research notes about the stock. ROTH Capital stated their Buy rating for the stock in a research note on February 19, 2020, with the firm’s price target at $18.